Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist

Cardiovascular Drug Reviews

Volumn 22, Issue 4, 2004, Pages 285-308

  Yoshida, Kazunori ^a   Kohzuki, Masahiro ^b  

^a Furukawa City Hospital   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II antagonists; Antihypertensive drugs; CS 866; Hypertension; Olmesartan medoxomil

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALKALOID; ALUMINUM MAGNESIUM HYDROXIDE; AMLODIPINE BESYLATE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; CAPTOPRIL; CYTOCHROME P450; DIGOXIN; DRUG METABOLITE; EPROSARTAN; FELODIPINE; FUROSEMIDE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; MONOCROTALINE; OLMESARTAN; PENTOSIDINE; PRAVASTATIN; PROADIFEN; PRODRUG; SARALASIN; TEMOCAPRIL; UNINDEXED DRUG; VALSARTAN; WARFARIN;

ADULT; AGED; AREA UNDER THE CURVE; ATHEROSCLEROSIS; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EDEMA; ESSENTIAL HYPERTENSION; ESTERIFICATION; HEART INFARCTION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERLIPIDEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; REVIEW; SIDE EFFECT; SURVIVAL; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION;

EID: 12244258508     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2004.tb00147.x     Document Type: Review

References (44)

1. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001;19(Suppl 1):S49-S56.
2. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
3. 1-receptor antagonist. J Hypertens 2001;19(Suppl 1):S15-S20.
4. Burnier M, Brunner. Angiotensin II receptor antagonist. Lancet 2000;355:637-645.
5. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17:425-432.
6. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003.
7. Gardner SF, Franks AM. Olmesartan medoxomil: The seventh angiotensin receptor antagonist. Ann Pharmacother 2003;37:99-105.
8. GISEN Group. Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857-1863.
9. Ichikawa S, Takayama Y. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001;24:641-646.
10. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: A review of the literature and pathophysiology. Ann Intern Med 1992;117:234-242.
11. 1R antagonist, on spinal motor neurons in vitro and in vivo. Neurol Res 2002;24:468-472.
12. 1 expression. Hypertens Res 2003;26:737-742.
13. 1 receptor on intimal hyperplasia in balloon-injured rat artery. Arterioscler Thromb Vasc Biol 2002;22:1299-1304.
14. Kobayashi N, Fujimori I, Watanabe M, Ikeda T. Real-time monitoring of metabolic reactions by microdialysis in combination with tandem mass spectrometry: Hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines. Anal Biochem 2000;287:272-278.
15. 1 receptor antagonist. J Hypertens 2001;19(Suppl 1):S3-S14.
16. Kurikawa N, Suga M, Kuroda S, Yainada K, Ishikawa H. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br J Pharmacol 2003;139:1085-1094.
17. Laeis P, Püchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001;19(Suppl 1):S21-S32.
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
19. 1 receptor blocker on neointima formation. Hypertension 2002;40:451-457.
20. Miyazaki M, Takai S. Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens 2002;16(Suppl 2):S7-S12.
21. Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995;285:181-188.
22. 1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002;25:271-278.
23. Mukai Y, Shimokawa H, Higashi M, et al. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol 2002;22:1445-1450.
24. Nakamura Y, Yoshiyama M, Omura T, et al. Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction. Cardiovasc Res 2003;57:48-54.
25. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003;14:1212-1222.
26. Neutel JM. Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001;87(Suppl):37C-43C.
27. Neutel JM, Elliott WJ, Izzo JL, Chen CL, Masonson HN. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurement. J Clin Hypertens 2002;4:325-331.
28. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001;3:283-291.
29. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
30. Püchler K. Nussberger J, Laeis P, Witte PU, Brunner HR. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 1997;15:1809-1812.
31. Schwocho LR, Masonson HN. Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001;41:515-517.
32. Sealy JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Laragh JH, Brenner BM, ed. Hypertension: Pathophysiolog, Diagnosis and Management. New York: Raven Press, 1990;1287-1317.
33. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002;16(Suppl 2):S24-S28.
34. 1 receptor blocker follow a relatively low dose of ACE inhibitor initiated in acute myocardial infarction? Cardiovasc Res 2003;58:610-620.
35. Takemoto M, Egashira K, Tomita H, et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: Effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997;30:1621-1627.
36. Taniyama Y, Morishita R, Nakagami H, et al. Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 2000;102:246-252.
37. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
38. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91:1269-1281.
39. van den Meiracker AH, Man in't Veld AJ, Admiraal PJJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and it affect the antihypertensive response? J Hypertens 1992;10:803-812.
40. von Bergmann K, Laeis P, Püchler K, Sudhop T, Schwocho LR, Gonzalez L. Olmesartan medoxomil: Influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001;19(Suppl 1):S33-S40.
41. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med 1988;319:1517-1525.
42. Yanagisawa H, Amemiya Y, Kanazaki T, et al. Nonpeptide angiotensin II receptor antagonists: Synthesis, biological activities, and structure-activity relationships of imidazole-5-carboxylic acids bearing alkyl, alkenyl, and hydroxyalkyl substituents at the 4-position and their related compounds. J Med Chem 1996;39:323-338.
43. Yoshida K, Perich R, Casley DJ, Johnston CI. Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two-kidney, one clip Goldblatt hypertensive rats. J Hypertens 1998;16:645-655.
44. Yoshida K, Xu H-L, Kawamura T, Ji L, Kohzuki M. Chronic angiotensin converting enzyme inhibition and angiotensin II antagonism in rats with chronic renal failure. J Cardiovasc Pharmacol 2002;40:533-542.